Evidence map›Paper›PMID 37244887›Full record

ArticleMolecular biology reports2023

Efficient site-specific integration in CHO-K1 cells using CRISPR/Cas9-modified donors.

Mohammad Hassan Kheirandish, Behnaz Rahmani, Hossein Zarei Jaliani, Farzaneh Barkhordari, Mohammad Ali Mazlomi, Fatemeh Davami

Open access · bronzeAbstract read
In one paragraph

Article in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mohammad Hassan KheirandishMedical Biotechnology Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Behnaz RahmaniBiotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Hossein Zarei JalianiDepartment of Medical Biotechnology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Farzaneh BarkhordariBiotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Mohammad Ali MazlomiMedical Biotechnology Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. ma.mazlomi@gmail.com.
Fatemeh DavamiBiotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. f.davami@gmail.com.ORCID http://orcid.org/0000-0002-7693-2926
Pasteur Institute of Iran · IRShahid Sadoughi University of Medical Sciences and Health Services · IRTehran University of Medical Sciences · IR

Funding

Tehran University of Medical Sciences and Health Services 99-1-148-47958
6 · The paper itself

Abstract

backgroundConventional methods applied to develop recombinant CHO (rCHO) cell line as a predominant host for mammalian protein expression are limited to random integration approaches, which can prolong the process of getting the desired clones for months. CRISPR/Cas9 could be an alternative by mediating site-specific integration into transcriptionally active hot spots, promoting homogenous clones, and shortening the clonal selection process. However, applying this approach for the rCHO cell line development depends on an acceptable integration rate and robust sites for the sustained expression. METHODS AND

resultsIn this study, we aimed at improving the rate of GFP reporter integration to the Chromosome 3 (Chr3) pseudo-attP site of the CHO-K1 genome via two strategies; these include the PCR-based donor linearization and increasing local concentration of donor in the vicinity of DSB site by applying the monomeric streptavidin (mSA)-biotin tethering approach. According to the results, compared to the conventional CRISPR-mediated targeting, donor linearization and tethering methods exhibited 1.6- and 2.4-fold improvement in knock-in efficiency; among on-target clones, 84% and 73% were determined to be single copy by the quantitative PCR, respectively. Finally, to evaluate the expression level of the targeted integration, the expression cassette of hrsACE2 as a secretory protein was targeted to the Chr3 pseudo-attP site by applying the established tethering method. The generated cell pool reached 2-fold productivity, as compared to the random integration cell line.

conclusionOur study suggested reliable strategies for enhancing the CRISPR-mediated integration, introducing Chr3 pseudo-attP site as a potential candidate for the sustained transgene expression, which might be applied to promote the rCHO cell line development.

Indexed as

Chromosomes, Human, Pair 3CRISPR-Cas SystemsAnimalsCell DifferentiationCHO CellsClone CellsCricetinaeCricetulusHumansCHO cell line developmentCRISPR/Cas9Donor designSite-specific integrationTethering approach

Identifiers

PMID37244887
PMCPMC10224643
OpenAlexW4378549384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.